Bio-Path Holdings (BPTH) Announces Presentation of BP1001 Phase 2 Data in AML at ASCO
Tweet Send to a Friend
Bio-Path Holdings, Inc., (Nasdaq: BPTH) announced that data from the Phase I study of BP1001 (Liposomal Grb2 Antisense) as a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
